Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit.

Rhea-AI Summary

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's management will engage in a fireside chat and be available for one-on-one meetings with registered investors during the event, which is scheduled for October 15-17, 2024.

Key details of Talphera's participation include:

• Event: 2024 Maxim Healthcare Virtual Summit
• Date: October 16, 2024
• Time: 3:00 PM ET / 12:00 Noon PT

Talphera focuses on developing and commercializing innovative therapies for use in medically supervised settings. Investors and interested parties can access the fireside chat through the provided webcast link.

News Market Reaction – TLPH

-2.57%

-2.57% Session move

In the trading session that priced this news, TLPH declined 2.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.

Event:  2024 Maxim Healthcare Virtual Summit

Date:   October 16, 2024

Time:   3:00 PM ET / 12:00 Noon PT

Webcast link:  2024 Maxim Healthcare Virtual Summit

About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual-summit-302270671.html

SOURCE Talphera, Inc.

FAQ

When is Talphera (TLPH) participating in the 2024 Maxim Healthcare Virtual Summit?

Talphera (TLPH) is participating in the 2024 Maxim Healthcare Virtual Summit on October 16, 2024, at 3:00 PM ET / 12:00 Noon PT.

What type of event is Talphera (TLPH) participating in at the 2024 Maxim Healthcare Virtual Summit?

Talphera (TLPH) management will be participating in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

Will Talphera (TLPH) be available for investor meetings during the 2024 Maxim Healthcare Virtual Summit?

Yes, Talphera (TLPH) management will be available for one-on-one meetings with registered investors during the 2024 Maxim Healthcare Virtual Summit.

What is the focus of Talphera (TLPH) as a pharmaceutical company?

Talphera (TLPH) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.